Minerva Surgical to Announce Fourth Quarter and Full Year 2022 Financial Results
Minerva Surgical, Inc. (Nasdaq: UTRS) will release its Q4 and full-year 2022 financial results on March 21, 2023. A conference call is scheduled for 1:30 PM PT / 4:30 PM ET that same day to discuss the results and company highlights. Minerva focuses on minimally invasive solutions for Abnormal Uterine Bleeding (AUB), aiming to provide alternatives to hysterectomy and improve women's uterine healthcare. The company offers a range of products designed to address common causes of AUB, enhancing treatment options while avoiding unnecessary surgeries.
- Scheduled release of Q4 and full-year 2022 financial results could indicate ongoing financial transparency.
- Focus on developing minimally invasive solutions showcases commitment to women's healthcare.
- None.
SANTA CLARA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that should be used to join the call.
The live webinar of the call may be accessed by visiting the Recent Events section of the company’s website at http://ir.minervasurgical.com. A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.
About Minerva Surgical, Inc.
Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The Company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies.
INVESTOR RELATIONS CONTACT
Caroline Corner
investors@minervasurgical.com
415-202-5678
RELATED LINKS
https://www.minervasurgical.com
FAQ
When will Minerva Surgical release its Q4 2022 financial results?
What time is the conference call for Minerva Surgical's financial results?
How can I access the webcast for Minerva Surgical's financial results?
What is Minerva Surgical's focus in the healthcare sector?
